260447-04-9

Basic information

• Product Name: 2,6-diMethyl-4-(5-nitropyridin-2-yl)Morpholine
• Synonyms: 2,6-Dimethyl-4-(5-nitro-2-pyridinyl)morpholine;2,6-diMethyl-4-(5-nitropyridin-2-yl)Morpholine;(2S,6R)-2,6-diMethyl-4-(5-nitropyridin-2-yl)Morpholine
• CAS NO: 260447-04-9
• Molecular Formula: C11H15N3O3
• Molecular Weight: 237.2551
• Mol File: 260447-04-9.mol
• Article Data: 13

Chemical Properties

• Boiling Point: 402.8±45.0 °C(Predicted)
• Appearance: /
• Density: 1.199±0.06 g/cm3(Predicted)
• Storage Temp.: Inert atmosphere,Room Temperature
• PKA: 1.56±0.24(Predicted)
• CAS DataBase Reference: 2,6-diMethyl-4-(5-nitropyridin-2-yl)Morpholine(CAS DataBase Reference)
• NIST Chemistry Reference: 2,6-diMethyl-4-(5-nitropyridin-2-yl)Morpholine(260447-04-9)
• EPA Substance Registry System: 2,6-diMethyl-4-(5-nitropyridin-2-yl)Morpholine(260447-04-9)

Safety Data

• Hazardous Substances Data: 260447-04-9(Hazardous Substances Data)

Usage

Uses

2,6-Dimethyl-4-(5-nitropyridin-2-yl)morpholine is a useful research chemical.

Upstream product

• 4548-45-2 2-chloro-5-nitropyridine 
• 276252-73-4 (+/-)-trans-2,6-dimethylmorpholine 
• 4214-76-0 5-nitro-pyridin-2-ylamine 
• 141-91-3 cis-2,6-dimethylmorpholine 
• 21655-48-1 cis-2,6-dimethylpiperazine 

Downstream Products

• 956699-06-2 6-(2,6-dimethyl-morpholin-4-yl)pyridin-3-ylamine 
• 1221721-86-3 3-bromo-N-(6-((2R,6S)-2,6-dimethylmorpholino)pyridin-3-yl)-2-methylbenzamide 
• 956697-53-3 Erismodegib 
• 1218778-77-8 N-[6-[(2R,6S)-2,6-dimethyl-4-morpholinyl]-3-pyridinyl]-2-methyl-4’-(trifluoromethoxy)-[1,1‘-biphenyl]-3-carboxamide diphosphate 
• 956699-06-2 (2S,6R)-2,6-dimethyl-4-(5-aminopyridin-2-yl)morpholine 

Relevant articles and documents

SMALL MOLECULE INHIBITORS OF DYRK/CLK AND USES THEREOF

This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a 6,5-heterocyclic structure (e.g., compounds having a imidazopyridine, imidazopyrimidine, imidazopyrazine, imidazopyridazine, imidazotriazine, benzoimidazole, benzotriazole, benzoisoxazole, purine, indazole, triazolotriazine, triazolopyridazine, triazolopyrimidine, triazolopyrazine, triazolotetrazine, triazolopyridine, pyrazolopyrazine, pyrazolopyrimidine, pyrazolopyridazine, pyrazolotriazine, pyrazolopyridine, isoxazolopyrazine, isoxazolopyrimidine, isoxazolopyrdiazine, isoxazolotriazine, or isoxalopyridine structure) which function as inhibitors of DYRK1A, DYRK1B, and Clk-1, and their use as therapeutics for the treatment of Alzheimer's disease, Down syndrome, diabetes, glioblastoma, autoimmune diseases, cancer (e.g., glioblastoma, prostate cancer), inflammatory disorders (e.g., airway inflammation), and other diseases.

Smo inhibitor as well as synthesis method and application thereof

The invention discloses an Smo inhibitor as well as a synthesis method and application thereof. A structural formula of the Smo inhibitor is shown by a formula (I) as shown in the specification. The invention also discloses the synthesis method and the application of the Smo inhibitor. According to the invention, nilotinib is optimized into the dual-targeted inhibitor being active against Smo andBcr-Abl, and the inhibitor can overcome the tolerance problem caused by single-targeted drugs, has the advantages of improving anti-tumor efficacy and reducing toxic or side effects, and provides a reference for future research on dual-targeted anti-hematologic malignant drugs.

Preparation methods of Sonidegib intermediate and Sonidegib

The invention provides preparation methods of a Sonidegib intermediate and Sonidegib. According to the preparation methods, 2-amino-5-nitropyridine (II) and R-propylene oxide (or S-propylene oxide) are subjected to an epoxy ring-opening substitution react